InvestorsHub Logo
Followers 116
Posts 1877
Boards Moderated 0
Alias Born 11/22/2017

Re: None

Monday, 02/18/2019 11:30:27 AM

Monday, February 18, 2019 11:30:27 AM

Post# of 700659
The lomustine crisis: awareness and impact of the 1500% price hike.

Neuro-Oncology, Volume 21, Issue 1, 1 January 2019, Pages 1–3, https://doi.org/10.1093/neuonc/noy189
Published: 22 December 2018

Lomustine was marketed by Bristol-Myers Squibb as CeeNU until 2013. At that time it was sold to NextSource Biotechology, a leading specialty pharmaceutical manufacturer and was re-branded as Gleostine. This is currently the only company producing lomustine in the United States. Since 2013, we have seen the cost of lomustine increase by >1500% from $50 to $768 per capsule.



https://academic.oup.com/neuro-oncology/article/21/1/1/5257427
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News